Health Canada

Health Canada

April 19, 2011 09:56 ET

Note to Editors: Health Canada

OTTAWA, ONTARIO--(Marketwire - April 19, 2011) - Health Canada today released the April 2011 issue of the Canadian Adverse Reaction Newsletter (CARN).

This issue includes an article on a suspected association between fluticasone propionate and bone cell death, a rare but serious side effect. Fluticasone propionate is a highly potent corticosteroid drug used to treat a variety of inflammatory conditions, including asthma and allergic rhinitis.

Of note to diabetic patients, the newsletter includes an article on a possible drug interaction between rosiglitazone and fenofibrate. Avandia, Avandamet and Avandaryl contain rosiglitazone and are used to treat diabetes, while fenofibrate is used to lower blood lipids. As well, the CARN includes an article on the smoking-cessation drug Champix (varenicline) and a suspected association with increased blood sugar levels in diabetics.

Finally, this issue contains an article on the anti-malarial drug quinine sulfate and reports of serious adverse reactions, along with a quarterly summary of communications to health professionals and the public.

The April 2011 edition of CARN can be viewed on the Health Canada Web site at:

Contact Information

  • Media Inquiries:
    Health Canada
    Media Relations